REPIC: RSV Entry Pathway in Human Ciliated Airway Cells
The search for roadblocks to viral infection of the human lung
Leiden University Medical Center (LUMC) and Janssen Vaccines & Prevention B.V. have finished a research collaboration effort to improve the prevention of respiratory viral infections. During this research collaboration, novel host proteins involved in viral replication have been identified. More specifically, removing these proteins from the host cell (the cell being targeted by RSV) resulted in a complete blocking of the infection. These highly encouraging experimental outcomes have led to the design of a drug development program. The goal of this program is to develop small molecule drugs that inhibit the function of these proteins.
Furthermore, LUMC and Janssen Vaccines & Prevention B.V. have built an assay on genetically modified lung cells allowing to test new antiviral drugs in a highly sensitive manner. This assay will be taken along in the development of the drugs described in the previous paragraph.
Other projects
In each PPP project, research institutions, businesses and healthcare organisations work together on a specific health challenge. Browse the full project overview.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.
Hoe kunnen we je helpen?
Heb je een vraag of wil je meer weten over Health Holland? We brengen je graag in contact met de juiste mensen, kennis en mogelijkheden om gezondheidsinnovatie te versnellen.
We have received your message
We will contact you within 3 to 4 working days. If your question is urgent, please contact us directly. Below is the contact option that best matches your subject.
Start again
Something went wrong while sending the form. Please try again.